Summary of experimental procedures and clinical features of subjects included in this study
| Route of immunisation | Diagnosis | No of fasting days | No of subjects | Age (years, mean (SD)) | Sex (M/F) | Disease duration (years, mean (SD)) | Treatment | ||||||||
| Corticosteroids | DMARD | Cytotoxic drugs | |||||||||||||
| Peroral | Seropositive RA | 6 | 5 | 49 (7) | 0/5 | 15 (6) | 80% | 60% | 20% | ||||||
| Seronegative polyarthritis | 3 | 1 | 60 | 0/1 | 1 | None | None | None | |||||||
| Controls | 6 | 5 | 36 (7) | 3/2 | — | — | — | — | |||||||
| Controls | 3 | 7 | 40 (8) | 3/4 | — | — | — | — | |||||||
| Controls | None | 4 | 38 (10) | 1/3 | — | — | — | — | |||||||
| Parenteral | Seronegative polyarthritis | 3 | 1 | 61 | 0/1 | 2 | None | None | None | ||||||
| Controls | 3 | 5 | 40 (10) | 2/3 | — | — | — | — | |||||||
| Controls | None | 3 | 42 (12) | 1/2 | — | — | — | — | |||||||
DMARD, disease modifying antirheumatic drugs.